Table 1 Examples of clinical trials using VOA

NCT01319383

Vorinostat (single dose) 8 patients

Single dose of vorinostat increased cell-associated RNA in resting CD4 cells but no reduction in IUPM

[26]

NCT01319383

Vorinostat (multiple doses 3 ×/week for 8 weeks) 5 patients

Increase in cell-associated RNA with multiple doses compared to single dose of vorinostat in 3/5 patients, no reduction in IUPM

[27]

NCT01319383

Vorinostat (multiple doses) 16 patients

Multiple doses of vorinostat increased cell-associated RNA in resting CD4 cells but no reduction in IUPM

[28]

NCT01680094

Panobinostat 15 patients

Increase in cell-associated RNA, increase in plasma viraemia, no significant reduction in total and integrated DNA or IUPM. No delay in time to rebound in the 9 patients undergoing planned treatment interruption.

[29]

NCT00289952

Valproic acid and ART 56 patients

No reduction in IUPM

[30]

NCT01286259

Disulfiram 16 patients

Transient increase in plasma viraemia in a subset of patients, no overall change in plasma viraemia in the entire cohort, no change in IUPM

[31]

NCT02443935

MGN1703 15 patients

Significant reduction in cell-associated RNA post-treatment, transient increase in plasma viraemia in 6/15 patients. No change in total or integrated HIV DNA, also no change in IUPM

[32]

NCT02092116

REDUC

Romidepsin, Vacc-4x and rhuGM-CSF 20 patients (17 completed trial)

Significant decrease (40%) in total DNA (in 16 patients measurable), non-significant decrease (19%) in integrated DNA (15 patients measurable) significant reduction (38%) in IUPM (6 patients measurable). No delay in time to rebound in the 15 patients who have undergone post treatment interruption

[19]

NCT02336074 RIVER

ART, Raltegravir, Vorinostat, ChAdV63.HIVconsv and MVA.HIVconsv

Ongoing

NCT02707900 VORVAX

Vorinostat and AGS-004

Ongoing

NCT02471430

ACTIVATE

Panobinostat and Pegylated Interferon-alpha2a

Ongoing

NCT02408861

Nivolumab and Ipilimumab

Ongoing